Date: 2017-01-09
Type of information: Clinical research agreement
Compound: CRS-207 and pembrolizumab
Company: Aduro Biotech (USA - CA) Merck&Co (USA - NJ)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism: immunotherapy product/monoclonal antibody/immune checkpoint inhibitor. Keytruda® (pembrolizumab - MK-3475) is a monoclonal anti-PD-1 antibody designed to restore the natural ability of the immune system to recognize and target cancer cells by selectively achieving dual ligand blockade (PD-L1 and PD-L2) of the PD-1 protein. By blocking PD-1, pembrolizumab enables activation of the immune system’s T-cells that target cancer by essentially releasing a brake on the immune system. CRS-207 is one of a family of product candidates based on Aduro's live-attenuated, double-deleted (LADD)Listeria monocytogenes immuno-oncology platform that are designed to induce potent innate and adaptive immune responses. CRS-207 has been engineered to express the tumor-associated antigen mesothelin, which is over-expressed in many cancers including mesothelioma and pancreatic, non-small cell lung, ovarian and gastric cancers.
Disease: gastric cancer
Details: * On January 9, 2017, Aduro Biotech announced a clinical collaboration with Merck&Co. The companies will investigate the combination of CRS-207, Aduro's LADD (live, attenuated double-deleted) based immunotherapy, with Merck's anti-PD-1 therapy Keytruda® (pembrolizumab) for the treatment of gastric cancer.
The multicenter Phase 1 study, planned to begin in the first half of the year, will enroll patients with metastatic gastric cancer who have failed at least two prior therapies to receive the combination of CRS-207 and pembrolizumab.
Financial terms:
Latest news:
